Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Affiliation
King's College London School of MedicineIssue Date
2008
Metadata
Show full item recordAbstract
Acute myeloid leukaemia (AML) is a difficult to treat disease and strategies, such as immunotherapy, which have the potential to eliminate residual tumour cells at first remission are required to reduce the incidence of relapse with its high associated mortality rates. T cells play an important role in tumor immunity and two signals are traditionally thought to be required to activate naive T cells; signal one through the major histocompatibility:antigen:T-cell receptor complex and signal two through costimulation. Many tumor associated antigens have been identified in AML suggesting it may be possible to target the immune system of AML patients; however AML develops due to tumour and immune editing, two systems by which AML cells can escape immune surveillance. By genetically modifying AML cells to express costimulatory molecules and/or cytokines, it has been possible to transform AML cells into antigen presenting cells and this has the potential to re-activate the immune system in patients. Here we summarize the rationale for using a whole cell vaccine approach to treat AML, and discuss current progress in the field of whole cell vaccine development against AML.Citation
Cheuk, A. & Guinn, B. (2008) 'Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine', Frontiers in Bioscience: a journal and virtual library, 13, pp.2022-2029.Publisher
bioscience.orgPubMed ID
17981688Additional Links
http://www.bioscience.org/2008/v13/af/2820/fulltext.htmType
ArticleLanguage
enISSN
1093-4715Sponsors
leukaemia and lymphoma researchCollections
Related articles
- Anti-tumor immunity in a model of acute myeloid leukemia.
- Authors: Cheuk AT, Wells JW, Chan L, Westwood NB, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA
- Issue date: 2009 Mar
- Development of a whole cell vaccine for acute myeloid leukaemia.
- Authors: Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA
- Issue date: 2006 Jan
- Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model.
- Authors: Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ, Croop JM
- Issue date: 1997 Nov-Dec
- Immunotherapy prospects for acute myeloid leukaemia.
- Authors: Barrett AJ, Le Blanc K
- Issue date: 2010 Aug
- Harnessing the immune system in acute myeloid leukaemia.
- Authors: Austin R, Smyth MJ, Lane SW
- Issue date: 2016 Jul